PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Articles|November 8, 2022
Achieve process flexibility with the Gibco™ HIP CHO AGT™ media
Author(s)Thermo Fisher
During therapy manufacture, consumable stability is vital to ensure flexible material handling and consistent results. This is particularly true for cell culture media, which is volumetrically the largest bioprocess material component, especially in perfusion workflows. In our new study, we explore the shelf-life of reconstituted Gibco™ High-Intensity Perfusion CHO Advanced Granulation Technology (AGT™) media (HIP CHO AGT media). Chemically defined and animal origin-free, this easy-to-use perfusion medium can provide flexibility with excellent post-reconstitution stability and help you achieve high titers in your CHO cell lines. Discover how HIP CHO AGT media can support the optimization of your monoclonal antibody (mAb) manufacturing.
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.